

A Leap from the Foundation to Fine Art
HBP SURGERY WEEK 2020

JULY 27-29, 2020 SEOUL DRAGON CITY, SEOUL, KOREA
www.khbps.org

& The 52nd Annual congress of the
Korean Association of HBP Surgery



CURRICULUM VITAE

Name in Full : Seung Woo Park
Date of Birth : November 20, 1965
Nationality : Republic of Korea
Sex : Male
Present Position : Professor, Department of Internal Medicine, Institute of
Gasterology, Yonsei University College of Medicine.
Fax : 822-393-6884
Tel : 822-2228-1964
: 82-010-3802-1965
E-mail : swoopark@yuhs.ac
Mailing Address : Department of Internal Medicine,
50 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Korea



Education

1984. 3 - 1990. 2 : College of Medicine, Yonsei University
1993. 3 - 1995. 2 : Master Course of Medical Science, Graduate School,
Yonsei University
1998. 3 – 2003.8 : Ph.D Course of Medical Science, Graduate School,
Yonsei University, Majored in Gastroenterology
2004. 1-2006.1 : PostDoc. Fellowship, Department of Surgical Oncology,
Jonhs Hopkins Medical Institution

Professional Training & Employment

1990. 3 - 1991. 2 : Internship at Severance Hospital
Yonsei University College of Medicine
1991. 3 - 1995. 2 : Residency at the Dept. of Medicine, Severance Hospital,
Yonsei University College of Medicine
1995. 2 - 1998. 4 : Military Service as a Military Medical Officer
1998. 5 – 2000.2 : Fellowship course at the Department of Internal Medicine
Yonsei University College of Medicine

A Leap from the Foundation to Fine Art
HBP SURGERY WEEK 2020

& The 52nd Annual congress of the
 Korean Association of HBP Surgery

JULY 27-29, 2020 SEOUL DRAGON CITY, SEOUL, KOREA
www.khbps.org



- 2000. 3 – 2001.2 : Medical instructor at the Department of Internal Medicine
 Yonsei University College of Medicine
- 2001. 3- 2006.2 : Assistant professor at the Department of Internal Medicine
 Yonsei University College of Medicine
- 2006.2-2011.2 : Associate professor at the Department of Internal Medicine
 Yonsei University College of Medicine
- 2011.3-Present : Professor at the Department of Internal Medicine
 Yonsei University College of Medicine
- 2014.3-Present : Department Head of Postgraduate School of Nano Science
 and Technology, Yonsei University
- 2015.3-Present : Head of Pancreatobiliary Cancer Center, Yonsei Cancer
 Hospital

Research Interest

Clinical field: Pancreas and biliary tract cancer, Anticancer chemotherapy, Immune cell therapy (NK cells, CAR-T cells), Therapeutic endoscopy

Basic research field: Carcinogenesis, Cancer stem cell, Zebrafish disease model

Representative papers

Title	Publish	ISSN	Year	Role	Impact Factor
Iroquios homeobox 1 acts as a true suppressor in multiple organs by regulating cell cycle progression	Neoplasia in press	1476-5586	2019	Corresponding author	5.9
Knockout of longevity gene <i>Sirt1</i> in zebrafish leads to oxidative injury, chronic inflammation, and reduced life span.	Plosone 2019 in press	1932-2103	2019	Corresponding author	2.8
In vivo study of natural killer (NK) cell cytotoxicity against cholangiocarcinoma in a nude mouse model.	In vivo		2018	Corresponding author	1.6
Impaired lymphocytes development and xenotransplantation of gastrointestinal tumor cells in Prkdc-null SCID zebrafish model	Neoplasia 2016 18:468-479	1476-5586	2016.8	Corresponding	5.9

A Leap from the Foundation to Fine Art
HBP SURGERY WEEK 2020

& The 52nd Annual congress of the
 Korean Association of HBP Surgery

JULY 27-29, 2020 SEOUL DRAGON CITY, SEOUL, KOREA



Predominant Activation of JAK/STAT3 Pathway by Interleukin-6 Is Implicated in Hepatocarcinogenesis	Neoplasia 2015 17:586-597	1476-5586	2015.7	Corresponding	5.9
Glioma is formed by active Akt1 alone and promoted by active Rac1 in transgenic zebrafish	Neuro Oncol. 2013 Mar;15(3):290-304.	1522-8517	2013.03	Corresponding	6.18
A magnetic switch for the control of cell death signalling in in vitro and in vivo systems.	Nature Materials 11,1038-1043(2012)	1476-1122	2012.10	Co-author	35.75
Aberrant Hedgehog Ligands Induce Progressive Pancreatic Fibrosis by Paracrine Activation of Myfibroblasts and Ductular Cells in Transgenic Zebrafish.	PlosOne. 2011;6:e27941	1932-6203	2011.11	Corresponding	4.51
Prospective Phase II Trial of Gemcitabine in Combination with Irinotecan as First-Line Chemotherapy in Patients with Advanced Biliary Tract Cancer.	Chemotherapy 2011;57:236-243	0009-3157	2011	Corresponding	2.06
Oncogenic KRAS induces progenitor cell expansion and malignant transformation in zebrafish exocrine pancreas	Gastroenterology 2008;134:2080-2890	0016-5085	2008.06.01	First	12.8
Capacitance-Based Assay for Real-Time Monitoring of Endocytosis and Cell Viability	Lab. Chip. 12;2377-84	1473-0197	2012	Co-author	5.67
Safety evaluation of self-expanding metallic biliary stents eluting gemcitabine in a porcine model	J Gastroenterol Hepatol 27(2):261-7	0815-9319	2012	Corresponding	2.86
Immunohistochemical analysis of claudin expression in pancreatic cystic tumors.	Oncol Reports 2011;25:971-978	1021-335X	2011	Corresponding	1.69
Phase II trial of S-1 and concurrent radiotherapy in patients with locally advanced pancreatic cancer	Cancer chemotherapy pharmacology 2009;63:535-541	0344-5704	2009	Corresponding	2.76
Intraductal ultrasonography combined with percutaneous transhepatic cholangioscopy for the preoperative evaluation of longitudinal tumor extent in hilar cholangiocarcinoma	J Gastroenterol Hepatol 63:535-541	0815-9319	2009	Corresponding	2.86

I hereby declare that the above statement is correct and true.

Sincerely Yours,

2020. 07. 13. Seung Woo Park, M.D.